Literature DB >> 19087140

Management of patients with neutralizing antibodies against interferon-beta: stop IFN-beta therapy or wait for the antibodies to go away?

P S Sorensen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19087140     DOI： 10.1111/j.1468-1331.2008.02265.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN： 1351-5101            Impact factor:   6.089


× No keyword cloud information.
  3 in total

1.  The impact of neutralizing antibodies on the risk of disease worsening in interferon β-treated relapsing multiple sclerosis: a 5 year post-marketing study.

Authors:  D Paolicelli; M D'Onghia; F Pellegrini; V Direnzo; P Iaffaldano; V Lavolpe; M Trojano
Journal:  J Neurol       Date:  2013-02-17       Impact factor: 4.849

Review 2.  Antidrug Antibodies Against Biological Treatments for Multiple Sclerosis.

Authors:  Per Soelberg Sorensen
Journal:  CNS Drugs       Date:  2022-05-19       Impact factor: 6.497

3.  Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway.

Authors:  Isaac Hurtado-Guerrero; Maria Jesus Pinto-Medel; Patricia Urbaneja; Jose Luis Rodriguez-Bada; Jesús Ortega-Pinazo; Pedro Serrano; Óscar Fernández; Laura Leyva; Begoña Oliver-Martos
Journal:  Sci Rep       Date:  2017-11-29       Impact factor: 4.379
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.